

## Review Article

# Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer

Ashraf Abusamra, Esam Murshid<sup>1</sup>, Hussain Kushi<sup>2</sup>, Sultan Alkhateeb<sup>3</sup>, Mubarak Al-Mansour<sup>4</sup>, Ahmad Saadeddin<sup>5</sup>, Danny Rabah<sup>6</sup>, Shouki Bazarbashi<sup>7</sup>, Mohammed Alotaibi<sup>8</sup>, Abdullah Alghamdi<sup>9</sup>, Khalid Alghamdi<sup>10</sup>, Abdullah Alsharm<sup>11</sup>, Imran Ahmad<sup>12</sup>

Department of Surgery, Urology Section, King Khalid Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, <sup>2</sup>Department of Radiation Oncology, Princess Norah Oncology Center, King Abdulaziz Medical City, <sup>4</sup>Department of Oncology, King Abdulaziz Medical City and King Saud Bin Abdulaziz University for Health Sciences, Jeddah, <sup>1</sup>Department of Oncology, Oncology Center, Prince Sultan Medical Military City, <sup>3</sup>Department of Surgery, Division of Urology, King Abdulaziz Medical City and King Saud Bin Abdulaziz University for Health Sciences, <sup>5</sup>Department of Oncology, King Abdulaziz Medical City, <sup>6</sup>Department of Surgery, College of Medicine and Uro-Oncology Research Chair, King Saud University, <sup>7</sup>Department of Oncology, Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Departments of <sup>8</sup>Urology and <sup>12</sup>Oncology, King Faisal Specialist Hospital and Research Centre, <sup>9</sup>Department of Urology, Prince Sultan Medical Military Center, <sup>10</sup>Department of Surgery, Division of Urology, Security Forces Hospital, <sup>11</sup>Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia

### Abstract

This is an update to the previously published Saudi guidelines for the evaluation, medical, and surgical management of patients diagnosed with prostate cancer. It is categorized according to the stage of the disease using the tumor node metastasis staging system 7<sup>th</sup> edition. The guidelines are presented with supporting evidence level, they are based on comprehensive literature review, several internationally recognized guidelines, and the collective expertise of the guidelines committee members (authors) who were selected by the Saudi oncology society and Saudi urological association. Considerations to the local availability of drugs, technology, and expertise have been regarded. These guidelines should serve as a roadmap for the urologists, oncologists, general physicians, support groups, and health care policy makers in the management of patients diagnosed with adenocarcinoma of the prostate to.

**Key Words:** Guidelines, management, prostate cancer, Saudi oncology society, Saudi urological association

### Address for correspondence:

Dr. Sultan Alkhateeb, Department of Surgery, Division of Urology, King Abdulaziz Medical City, King Saud Bin Abdulaziz University for Health Sciences, P. O. Box: 22490 (1446), Riyadh 11426, Saudi Arabia. E-mail: [alkhateeb@medknow.com](mailto:alkhateeb@medknow.com)

**Received:** 08.11.2015, **Accepted:** 15.11.2015

## INTRODUCTION

In Saudi Arabia, prostate cancer is the 6<sup>th</sup> most common cancer among men of all ages and the most common cancer among

men over the age of 75. There were 280 cases of prostate cancer accounting for 6.1% of all newly diagnosed cases among males

Access this article online	
Quick Response Code:	Website: <a href="http://www.urologyannals.com">www.urologyannals.com</a>
	DOI: 10.4103/0974-7796.176872

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**How to cite this article:** Abusamra A, Murshid E, Kushi H, Alkhateeb S, Al-Mansour M, Saadeddin A, *et al.* Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. *Urol Ann* 2016;8:123-30.

in 2010 with an age-standardized incidence rate of 5.5/100,000 among the male population, the median age at diagnosis was 73 years (range 2–105 years). Stage at the time of diagnosis is localized in 17.5% of cases with the remainder being either locally advanced (9.6%), metastatic (28.9%), or unknown (43.9%).<sup>[1]</sup>

Notably, there had been a steady increase in the number of reported cases in the Saudi cancer registry for the last two decades, which could be secondary to wider prostate-specific antigen (PSA) utilization, improved documentation, and reporting. More than 95% of primary prostate cancers are adenocarcinomas, so these guidelines are focused on this category of prostate tumors.

### PURPOSE AND METHODS

This is an update to the previously published Saudi guidelines for the evaluation, medical, and surgical management of prostate cancer.<sup>[2,3]</sup> It is categorized according to the stage of the disease using the tumor node metastasis staging system 7<sup>th</sup> edition. The guidelines are presented with supporting evidence level according to an article accompanying the guidelines 1<sup>st</sup> edition, as well as, the scope, purpose, and methods of these guidelines.<sup>[4]</sup> They are based on comprehensive MEDLINE and Cochrane Library English only literature review (1966 to December 2014), hand-searching journals, reviewing conference proceedings, and the collective expertise of the guidelines committee members [Table 1] who were appointed by the Saudi urological association and Saudi oncology society (comprised uro-oncologists, radiation oncologists [genitourinary focused interest and practice], and medical/clinical oncologists [genitourinary focused interest and practice]). The first version of these guidelines committee included an additional general urologists, general radiation oncologists, and general medical oncologists. Considerations to the local availability of drugs, technology, and expertise have been regarded, as well as, considerations of both benefits and harms, side effects, and risks. To formulate the recommendations, final decisions were taken by a voting system. External review of the guidelines was done before submission for publication.

### GUIDELINES

These guidelines should serve as a roadmap to provide guidance on the most effective therapeutic treatment and management of patients diagnosed with adenocarcinoma of the prostate to urologists, oncologists, general physicians, support groups, and healthcare policy makers.

#### Diagnosis and staging evaluation

When a biopsy is indicated, then a systematic transrectal ultrasound guided 10–12 core biopsies should be performed

or a multi-parametric magnetic resonance imaging (MRI)/ultrasound fusion targeted biopsy if available.

Once diagnosis is confirmed, the following staging evaluation should be done:

- Computed tomography (CT) or MRI abdomen and pelvis:
- Should only be done when the cancer is considered high-risk according to D'Amico risk groups (EL-2)<sup>[5,6]</sup>
  - Bone scan: Should only be done if any of the following (EL-2):<sup>[7-10]</sup>
    - PSA level >20 ng/mL
    - Patients with bony pain
    - Gleason score ≥ 8
    - Patient with clinical stage T3 or T4
    - Hypercalcemia or high serum alkaline phosphatase.

#### Staging classification

The tumor node metastasis AJCC staging 7<sup>th</sup> edition should be used.<sup>[11]</sup>

#### Management options

The management options depend on the stage (localized vs. metastatic), the risk group, and life expectancy.<sup>[12]</sup> The approach to treatment is influenced by patient's age, general condition, and coexisting medical problems, as well as his preferences. Side effects of various forms of treatment should be considered in selecting appropriate management.

##### Localized disease (cT1–cT2)

Any benefits of definitive local therapy with curative intent may take years to emerge. Therefore, therapy with curative intent is usually reserved for men with a sufficiently long life expectancy.

##### Low-risk

Options of therapy depend on the following factors:

- If the patient is asymptomatic with life expectancy <5 years: No further intervention required until symptomatic or clinical progression (EL-2)<sup>[13-15]</sup>
- If asymptomatic with life expectancy between 5 and 10 years: Active surveillance (involves active monitoring of the course of disease with the expectation to intervene with curative intent if cancer progresses) (EL-2)<sup>[13-15]</sup>
- If asymptomatic with life expectancy >10 years: Options include active surveillance, radical prostatectomy (RP), external-beam radiation therapy (EBRT), or brachytherapy (EL-2)<sup>[15-18]</sup>

**Table 1: D'Amico risk groups**

Low-risk	Intermediate risk	High-risk
T1–T2a and GS ≤6 and PSA ≤10	T2b and/or GS=7 and/or PSA >10–20	≥T2c or GS 8–10 or PSA >20

PSA: Prostate-specific antigen, GS: Gleason score

- The strategy behind active surveillance is to defer therapy for the clinically localized disease but regularly follow the patient and initiate local therapy with curative intent if there are any signs of local tumor progression. Active surveillance candidates must have all the following criteria: PSA <10, Gleason sum ≤6, number of positive cores ≤2, percentage of cancer involvement in any positive core <50%, and PSA density <0.15. Follow-up should entitle history, physical examination and PSA every 3–6 months, and repeated biopsy every 12–18 months (at least once); radical therapy should be offered if PSA velocity >0.35 ng/mL/year or progression in any of the aforementioned criteria<sup>[19-24]</sup>
- All RPs should be done in tertiary care centers by high-volume surgeons (EL-2); surgeon experience has been associated with improved recovery of postoperative continence and erectile function, with a very low surgical mortality<sup>[25,26]</sup>
- Lymphadenectomy can be omitted if the chance of being positive is <5% according to nomograms (EL-2)<sup>[27]</sup>
- Intensity-modulated EBRT is the minimal standard of EBRT, in which the only acceptable biological dose is ≥74 Gy (EL-2).<sup>[28-31]</sup>

#### Intermediate risk

Options of therapy depend on the following:

- If life expectancy is <5 years: Patient will have no further intervention until he becomes symptomatic or clinical progression (EL-2)<sup>[13,15]</sup>
- If life expectancy is between 5 and 10 years: Options include active surveillance, RP, or EBRT with 6 months of androgen deprivation therapy (ADT) (EL-2)<sup>[15-17,32-35]</sup>
- If life expectancy is more than 10 years: Options are RP with lymphadenectomy (lymph node dissection [LND])<sup>[36]</sup> (EL-1) or EBRT + 6 months of ADT (EL-2).<sup>[32-35]</sup>

#### High-risk

Options include EBRT (may include pelvic lymph nodes) with 18 months of ADT,<sup>[37-48]</sup> (EL-1) or RP with LND<sup>[49,50]</sup> (EL-3). Patients who have the advanced local disease and are unfit for the above mentioned two options may be candidates for castration or high-dose bicalutamide, when PSA level exceeds 10–15 ng/mL (EL-1).<sup>[51-53]</sup>

- RP patients who have pT3 (extraprostatic extension, or seminal vesicle invasion), final Gleason score ≥8, or positive margin with undetectable postoperative PSA, may undergo adjuvant EBRT to the prostatic bed (64–66 Gy) (EL-2)<sup>[54-60]</sup>
- Follow-up after curative therapy: Patients should have a disease-specific history, serum PSA at 3, 6, and 12 months after therapy, and then every 6 months for 3 years and then annually (EL-3).<sup>[61]</sup>

#### Management of recurrence postradical prostatectomy

- Definition: Recurrence post-RP is defined by PSA level >0.2 ng/mL in two consecutive readings<sup>[61-65]</sup>
- Factors helping to differentiate local relapse or distant metastasis are: The timing of PSA recurrence, PSA doubling time (PSADT), pathological stage, and final Gleason score<sup>[66,67]</sup>
- Treatment of local recurrence is early salvage EBRT preferably with ADT, which results are improved if given with lower PSA value (<0.5)<sup>[68-78]</sup>
- In biochemical recurrence, bone scan and CT are of no diagnostic value unless PSA value is higher than 20 ng/dL,<sup>[79-81]</sup> Gleason >7, or clinically indicated (EL-2).

#### Management of local recurrence after external beam radiation therapy

- Definition: A PSA rise 2 ng/mL above PSA nadir is the most reliable indication for recurrence (EL-2).<sup>[82,83]</sup> However, local recurrence is defined by the presence of all of the following: A prostatic biopsy showing malignant cells 18 months or longer after EBRT, associated rise in PSA, and no evidence of distant metastasis documented by CT scan or MRI, and bone scan<sup>[84,85]</sup>
- Options of therapy include: Observation up to PSA of 10 ng/dL then ADT,<sup>[86]</sup> or in carefully selected patients, salvage prostatectomy or brachytherapy may be considered.<sup>[87-89]</sup>

#### Advanced disease (including recurrence and metastasis)

##### Hormone naive disease

- ADT palliates symptoms and reduces the risk for potentially catastrophic sequelae of advanced disease (spinal cord compression, pathological fractures, ureteral obstruction, and extraskeletal metastasis) and may improve survival (EL-1).<sup>[90-92]</sup>
- Options of ADT include: Bilateral orchiectomy (including subcapsular), luteinizing hormone releasing hormone (LHRH) antagonist, LHRH agonists, and complete androgen blockade (CAB) continuous or intermittent<sup>[93-95]</sup>
- When treating with LHRH agonists, a concomitant anti-androgen during the initial 4 weeks must be given, to counteract the testosterone surge; also, it should be preceded with 7–10 days of anti-androgen, in patients with significant disease burden, to prevent flare of symptoms
- Metabolic, cardiovascular, and bone complications preventive measures for patients on ADT should be considered Check 4.<sup>[96,97]</sup> Bone health in prostate cancer patients
- Patients with high initial PSA, short PSADT (<12 months), pain at diagnosis, locally advanced

disease, or Gleason score  $\geq 8$  should preferably receive CAB (EL-2)<sup>[98-103]</sup>

- Castrate level of testosterone should be  $<20$  ng/dL (0.7 nmol/L), early morning sample<sup>[104-107]</sup>
- In case of intermittent androgen blockade (EL-2), the following should be observed:<sup>[108-121]</sup>
  - CAB (anti-androgen and LHRH) or LHRH antagonist should be used
  - Initial induction cycle should last 6–9 months
  - Treatment is usually stopped only if the patient is compliant, showing good PSA response with PSA  $<4$  ng/dL in patients with metastatic disease and  $<0.5$  ng/dL in biochemical relapse postlocal therapy, otherwise, should be on continuous ADT. PSA monitoring every 2–3 months is essential
  - Therapy is re-instituted for 3–6 months cycle if PSA reaches 10–15 ng/dL in metastatic disease or 4 ng/dL in biochemical relapse postlocal therapy.
- In general, use of steroidal anti-androgens should be discouraged
- In high-risk hormone sensitive patients (defined as patients with visceral metastases or  $\geq 4$  bone metastases [at least one nonaxial]), ADT plus 6 cycles of docetaxel have shown an excellent survival advantage over ADT alone (EL-I).<sup>[122]</sup>

#### Castrate resistant prostate cancer

- Definition: Two consecutive rises in PSA in the presence of castrate testosterone level
- The care of castrate-resistant prostate cancer (CRPC) patients should be coordinated through or taking place in a hospital with specialized oncology service. Therapy options depend on the presence or absence of metastases
- In non-metastatic CRPC (mCRPC), observation is preferred, but treatment with secondary hormonal manipulations may be offered by either adding or switching an anti-androgen, anti-androgen withdrawal, ketoconazole, steroids, diethylstilbestrol, or other estrogens<sup>[123-127]</sup>
- In asymptomatic or minimally symptomatic mCRPC (not needing opiates), treatment options include abiraterone with prednisone, enzalutamide, systemic chemotherapy (docetaxel with prednisone) (EL-I)<sup>[128-134]</sup>
- In highly symptomatic patients with good performance, systemic chemotherapy (docetaxel with prednisone) is the treatment of choice.<sup>[128-135]</sup> Systemic chemotherapy should be offered only to patients with performance status 0–2 by Eastern Cooperative Oncology Group scale. The decision when to start chemotherapy should depend on factors like PSADT and severity of symptoms (EL-I). For highly symptomatic patients with poor performance

status, they may be offered abiraterone with prednisone or enzalutamide (EL-3)

- Patients who fail docetaxel (prior docetaxel), have several options of therapy including: Cabazitaxel with prednisone, abiraterone acetate with prednisone, or enzalutamide (if not received in chemo-naïve setting); in addition, may also be offered alpharadin (radium 223) where available, if metastasis are limited to bone<sup>[136-140]</sup>
- Clinicians should offer palliative care to patients with mCRPC with poor performance status who received prior docetaxel chemotherapy. Alternatively, for selected patients, clinicians may offer treatment with abiraterone + prednisone, enzalutamide, or radionuclide therapy (EL-3)
- Clinical progression (symptoms, imaging) should be considered primarily in deciding success/failure of CRPC treatment options
- Patients with CRPC who were receiving LHRH antagonist/agonists should continue them indefinitely (EL-3).<sup>[141-143]</sup>

#### Bone health in prostate cancer patients

- All patients receiving any form of ADT should be prescribed Vitamin D (800 IU) and calcium supplements (1200 mg). Initial and periodic assessment of bone density and fracture risk may be beneficial in these patients. At risk patients (T score  $<-1.5$ ) treatment with either denosumab (60 mg every 6 months) or bisphosphonates can prevent bone loss associated with ADT<sup>[97]</sup>
- Patients with bony mCRPC should receive rank-ligand antibodies (denosumab) therapy 120 mg every 4 weeks to reduce skeletal-related events (bone pain, pathological fractures, bone radiation or surgery, and spinal cord compression) (EL-I), however, when not available zoledronic acid can be given (EL-I).<sup>[144-149]</sup>

#### Financial support and sponsorship

Nil.

#### Conflicts of interest

There are no conflicts of interest.

#### REFERENCES

1. Saudi Cancer Registry Annual Report; 2010. Available from: <http://www.scr.org.sa>. [Last accessed on 2014 May 17].
2. Abusamra AJ, Bazarbashi S, Bahader Y, Kushi H, Rabah D, Al Bogami N, et al. Saudi oncology society clinical management guidelines for prostate cancer. *Urol Ann* 2011;3 Suppl:S10-6.
3. Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Mahmood R, Almansour M, et al. Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. *Urol Ann* 2014;6:278-85.
4. Bazarbashi S. Why local guidelines? *Urol Ann* 2011;3 Suppl:S1-2.
5. Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An

- updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. *BJU Int* 2013;111:22-9.
6. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, *et al.* The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis. *Clin Radiol* 2008;63:387-95.
  7. Kemp PM, Maguire GA, Bird NJ. Which patients with prostatic carcinoma require a staging bone scan? *Br J Urol* 1997;79:611-4.
  8. Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, *et al.* Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. *Int J Radiat Oncol Biol Phys* 2000;48:1443-6.
  9. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. *JAMA* 1993;269:57-60.
  10. Huncharek M, Muscat J. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. *Cancer Invest* 1995;13:31-5.
  11. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, *et al.* *AJCC Cancer Staging Manual*. 7<sup>th</sup> ed. New York: Springer; 2010. p. 457-68.
  12. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, *et al.* Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998;280:969-74.
  13. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolphsson J, Jones GW, *et al.* Results of conservative management of clinically localized prostate cancer. *N Engl J Med* 1994;330:242-8.
  14. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. *JAMA* 1998;280:975-80.
  15. Klotz L. Active surveillance for prostate cancer: For whom? *J Clin Oncol* 2005;23:8165-9.
  16. Bill-Axelsson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, *et al.* Radical prostatectomy or watchful waiting in early prostate cancer. *N Engl J Med* 2014;370:932-42.
  17. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, *et al.* Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. *Int J Radiat Oncol Biol Phys* 2005;61:415-9.
  18. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, *et al.* 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. *J Urol* 2008;179 5 Suppl:S20-4.
  19. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. *J Clin Oncol* 2010;28:126-31.
  20. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, *et al.* Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. *J Clin Oncol* 2011;29:2185-90.
  21. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, *et al.* Natural history of early, localized prostate cancer. *JAMA* 2004;291:2713-9.
  22. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, *et al.* Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. *Eur Urol* 2009;55:1-8.
  23. Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P. Active surveillance for clinically localized prostate cancer – A systematic review. *J Surg Oncol* 2014;109:830-5.
  24. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, *et al.* Active surveillance for prostate cancer: A systematic review of the literature. *Eur Urol* 2012;62:976-83.
  25. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, *et al.* Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. *J Urol* 2003;170 (6 Pt 1):2292-5.
  26. Gore JL, Wright JL, Daratha KB, Roberts KP, Lin DW, Wessells H, *et al.* Hospital-level variation in the quality of urologic cancer surgery. *Cancer* 2012;118:987-96.
  27. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, *et al.* A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. *J Urol* 2003;170:1798-803.
  28. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, *et al.* Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys* 2008;70:67-74.
  29. Zietman AL, DeSilvio ML, Slater JD, Rossi C.J Jr., Miller DW, Adams JA, *et al.* Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. *JAMA* 2005;294:1233-9.
  30. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2013;85:686-92.
  31. Wilcox SW, Aherne NJ, Benjamin LC, Wu B, de Campos Silva T, McLachlan CS, *et al.* Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: Encouraging results for intermediate- and high-risk prostate cancer. *Onco Targets Ther* 2014;7:1519-23.
  32. Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, *et al.* Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. *BJU Int* 2012;110:1672-7.
  33. Toren P, Wong LM, Timilshina N, Alibhai S, Trachtenberg J, Fleshner N, *et al.* Active surveillance in patients with a PSA>10 ng/mL. *Can Urol Assoc J* 2014;8:E702-7.
  34. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. *JAMA* 2008;299:289-95.
  35. Zumsteg ZS, Spratt DE, Pei X, Yamada Y, Kalikstein A, Kuk D, *et al.* Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy. *Int J Radiat Oncol Biol Phys* 2013;85:1012-7.
  36. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. *Eur Urol* 2007;52:29-37.
  37. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, *et al.* Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. *J Clin Oncol* 2000;18:3904-11.
  38. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, *et al.* Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. *Int J Radiat Oncol Biol Phys* 2002;53:1097-105.
  39. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, *et al.* Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. *Lancet* 2002;360:103-6.
  40. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, *et al.* Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. *N Engl J Med* 1997;337:295-300.
  41. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, *et al.* Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. *Int J Radiat Oncol Biol Phys* 2001;50:1243-52.
  42. Pilepich MV, Winter K, Lawton CA, Krishn RE, Wolkov HB, Movsas B, *et al.* Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. *Int J Radiat Oncol Biol Phys* 2005;61:1285-90.
  43. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, *et al.* Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cyoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. *J Clin Oncol* 2003;21:3972-8.

44. Nabid A, Carrier N, Martin AG, Bahary JP, Souhami L, Duclos M, *et al.* High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. Presented at 2013 Genitourinary Cancers Symposium. *J Clin Oncol* 2013;31 Suppl 6:[Abstr 3].
45. Nabid A. Long-term quality of life in high-risk prostate cancer: Results of a phase III randomized trial. *J Clin Oncol* 2014;32 Suppl 4:[Abstr 5].
46. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, *et al.* External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. *Lancet Oncol* 2010;11:1066-73.
47. Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N. Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: A systematic review with meta-analyses. *Clin Oncol (R Coll Radiol)* 2014;26:e21-46.
48. Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nisticò C, *et al.* Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials. *BMC Cancer* 2010;10:675.
49. Yossepowitch O, Eggener SE, Bianco FJ Jr., Carver BS, Serio A, Scardino PT, *et al.* Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. *J Urol* 2007;178:493-9.
50. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: Influence of concomitant pathological variables. *J Urol* 2002;167:117-22. Erratum in: *J Urol* 2004;171 (2 Pt 1):811.
51. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, *et al.* Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. *J Clin Oncol* 2006;24:1868-76.
52. Studer UE, Whelan P, Wimpfing F, Casselman J, de Reijke TM, Knönagel H, *et al.* Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: Final results of EORTC randomized trial 30891 with 12 years of follow-up. *Eur Urol* 2014;66:829-38.
53. Kunath F, Grobe HR, Rucker G, Motschall E, Antes G, Dahm P, *et al.* Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. *Cochrane Database Syst Rev* 2014;6:CD009266.
54. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, *et al.* Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). *Lancet* 2005;366:572-8.
55. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, *et al.* Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. *J Clin Oncol* 2007;25:4178-86.
56. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, *et al.* Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. *Eur Urol* 2014;66:243-50.
57. Swanson GP, Thompson IM, Tangen C, Paradelo J, Cany-Hagino E, Crawford ED, *et al.* Update of SWOG 8794: Adjuvant radiotherapy for pT3 prostate cancer improves metastasis free survival. *Int J Radiat Oncol Biol Phys* 2008;72:S31.
58. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, *et al.* Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. *J Urol* 2009;181:956-62.
59. Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. *Cochrane Database Syst Rev* 2011;12:CD007234.
60. Chen C, Lin T, Zhou Y, Li D, Xu K, Li Z, *et al.* Adjuvant and salvage radiotherapy after prostatectomy: A systematic review and meta-analysis. *PLoS One* 2014;9:e104918.
61. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA* 1999;281:1591-7.
62. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, *et al.* Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. *J Clin Oncol* 2007;25:2035-41.
63. Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, *et al.* Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome – Results of a retrospective study. *Int J Radiat Oncol Biol Phys* 2009;73:1009-16.
64. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, *et al.* Management of prostate-specific antigen relapse in prostate cancer: A European Consensus. *Int J Clin Pract* 2004;58:382-90.
65. Moul JW. Prostate specific antigen only progression of prostate cancer. *J Urol* 2000;163:1632-42.
66. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, *et al.* Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. *Urology* 1994;43:649-59.
67. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. *J Urol* 1994;152 (5 Pt 2):1821-5.
68. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, *et al.* Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. *Int J Radiat Oncol Biol Phys* 2005;63:134-40.
69. Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. *J Clin Oncol* 2005;23:8192-7.
70. Patel R, Lepor H, Thiel RP, Taneja SS. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. *Urology* 2005;65:942-6.
71. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, *et al.* Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA* 2004;291:1325-32.
72. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. *J Urol* 2004;172 (6 Pt 1):2244-8.
73. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, *et al.* Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. *JAMA* 2008;299:2760-9.
74. Ost P, Lumen N, Goessaert AS, Fonteyne V, De Troyer B, Jacobs F, *et al.* High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. *Eur Urol* 2011;60:842-9.
75. King CR. The timing of salvage radiotherapy after radical prostatectomy: A systematic review. *Int J Radiat Oncol Biol Phys* 2012;84:104-11.
76. Ploussard G, Staerman F, Pierrelveclin J, Larue S, Villers A, Ouzzane A, *et al.* Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: Results from a national multicentre study. *World J Urol* 2014;32:1331-8.
77. Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, *et al.* Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. *Clin Genitourin Cancer* 2015;13:e1-6.
78. Kunath F, Keck B, Rucker G, Motschall E, Wullich B, Antes G, *et al.* Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: A systematic review. *BMC Cancer* 2013;13:131.
79. Cher ML, Bianco FJ Jr., Lam JS, Davis LP, Grignon DJ, Sakr WA, *et al.* Limited role of radionuclide bone scintigraphy in patients with

- prostate specific antigen elevations after radical prostatectomy. *J Urol* 1998;160:1387-91.
80. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, *et al.* Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. *Urology* 2003;61:607-11.
  81. Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: When is it indicated? *BJU Int* 2004;94:299-302.
  82. Consensus statement: Guidelines for PSA following radiation therapy. American society for therapeutic radiology and oncology consensus panel. *Int J Radiat Oncol Biol Phys* 1997;37:1035-41.
  83. Roach M 3<sup>rd</sup>, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, *et al.* Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. *Int J Radiat Oncol Biol Phys* 2006;65:965-74.
  84. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American society for therapeutic radiology and oncology consensus panel. *J Clin Oncol* 1999;17:1155.
  85. Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. *Int J Radiat Oncol Biol Phys* 2001;50:1212-9.
  86. Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. *Cancer* 2003;97:1127-33.
  87. Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21<sup>st</sup>-century radiotherapy. *Eur Urol* 2010;57:437-43.
  88. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys* 2010;77:1338-44.
  89. Moman MR, van der Poel HG, Battermann JJ, Moerland MA, van Vulpen M. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. *Brachytherapy* 2010;9:119-25.
  90. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, *et al.* Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. *Ann Intern Med* 2000;132:566-77.
  91. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, *et al.* Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. *Cancer* 2002;95:361-76.
  92. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, *et al.* Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. *Urology* 1998;51:389-96.
  93. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, *et al.* The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int* 2008;102:1531-8.
  94. Tombal B, Damber JE, Malmberg A, Persson BE, Klotz L, Iversen P. Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen for protection in the treatment of men with advanced prostate cancer. 2014 Genitourinary Cancers Symposium. *J Clin Oncol* 2014;32 Suppl 4:[Abstr 86].
  95. Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, *et al.* Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. *Eur Urol* 2014. pii: S0302-2838 (13) 01491-7.
  96. National Osteoporosis Foundation. National Osteoporosis Foundation clinician's Guide to Prevention and Treatment of Osteoporosis; 2013. Available from: <http://www.nof.org/professionals/clinical-guidelines>. [Last accessed on 2014 Mar 05].
  97. Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: How should the side effects be monitored and treated? *Clin Endocrinol (Oxf)* 2011;74:289-93.
  98. Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. *Cancer* 2009;115:3376-8.
  99. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. *BJU Int* 2004;93:1177-82.
  100. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. *Lancet* 2000;355:1491-8.
  101. Schmitt B, Bennett C, Seidenfeld J, Samson D, Wilt T. Maximal androgen blockade for advanced prostate cancer. *Cochrane Database Syst Rev* 2000;2:CD001526.
  102. Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, *et al.* Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review. *Urology* 2001;57:727-32.
  103. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, *et al.* Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. *Cancer* 2009;115:3437-45.
  104. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making. *Urology* 2000;56:1021-4.
  105. Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, *et al.* Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. *J Urol* 2007;178 (4 Pt 1):1290-5.
  106. Dason S, Allard CB, Tong J, Shayegan B. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. *Can Urol Assoc J* 2013;7:E263-7.
  107. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm. *J Urol* 2000;164:726-9.
  108. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. *Eur Urol* 2010;57:49-59.
  109. Hussain M, Tangen CM, Higano C, Schellhammer PF, Faulkner J, Crawford ED, *et al.* Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). *J Clin Oncol* 2006;24:3984-90.
  110. Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP Investigators Group. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: A randomized trial. *BJU Int* 2012;110:1262-9.
  111. Tunn UW, Canepa G, Hillger H, Fuchs W. Intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy- final results of a European randomized prospective phase-III clinical trial, AUO study AP 06/95, EC 507. *Am Urol Assoc* 2007; [Abstract 600].
  112. Miller K, Steiner U, Lingnau A, Keilholz U, Witzsch U, Haider A, *et al.* Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. *J Clin Oncol* 2007;25:5015.
  113. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, *et al.* Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Urooncological Group. *Eur Urol* 2009;55:1269-77.
  114. Irani J, Celhay O, Hubert J, Bladou F, Ragni E, Trape G, *et al.* Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: A randomised study. *Eur Urol* 2008;54:382-91.

115. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. *Urology* 2004;64:1182-6.
116. Cherrier MM, Aubin S, Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. *Psychooncology* 2009;18:237-47.
117. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, *et al.* International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: A meta-analysis of 1446 patients. *BJU Int* 2007;99:1056-65.
118. Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: Interim analysis of prognostic markers affecting initial response to androgen deprivation. *J Urol* 2008;180:915-9.
119. Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, *et al.* Intermittent androgen suppression for rising PSA level after radiotherapy. *N Engl J Med* 2012;367:895-903.
120. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, *et al.* Intermittent versus continuous androgen deprivation in prostate cancer. *N Engl J Med* 2013;368:1314-25.
121. Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, *et al.* Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: A systematic review and meta-analysis. *BMC Urol* 2014;14:9.
122. Sweeney C, Chen YH, Carducci MA, Liu G, Jarrard DF, Eisenberger M, *et al.* Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med* 2015;373:737-46.
123. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. *Urology* 2003 29;62 Suppl 1:87-94.
124. Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. *J Urol* 1993;150:908-13.
125. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, *et al.* Antiandrogen withdrawal in castrate-refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9426). *Cancer* 2008;112:2393-400.
126. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, *et al.* Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). *J Clin Oncol* 2004;22:1025-33.
127. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, *et al.* Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. *J Urol* 2008;180:921-7.
128. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, *et al.* Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013;368:138-48.
129. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, *et al.* Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). *Eur Urol* 2014;66:815-25.
130. Ryan CJ, Smith MR, Fizazi K, Miller K, Mulders P, Sternberg CN, *et al.* Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 2015;16:152-60.
131. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014;371:424-33.
132. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, *et al.* Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004;351:1502-12.
133. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. *J Clin Oncol* 2008;26:242-5.
134. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, *et al.* Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 2004;351:1513-20.
135. Cookson MS, Lowrance WT, Murad MH, Kibel AS; American Urological Association. Castration-resistant prostate cancer: AUA guideline amendment. *J Urol* 2015;193:491-9.
136. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, *et al.* Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med* 2011;364:1995-2005.
137. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, *et al.* Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 2012;13:983-92.
138. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012;367:1187-97.
139. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, *et al.* Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. *Lancet* 2010;376:1147-54.
140. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, *et al.* Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013;369:213-23.
141. Lee JL, Eun Kim J, Ahn JH, Lee DH, Lee J, Kim CS, *et al.* Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. *Am J Clin Oncol* 2011;34:140-4.
142. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. *J Clin Oncol* 1993;11:2167-72.
143. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report. *J Clin Oncol* 1994;12:1868-75.
144. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, *et al.* Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009;361:745-55.
145. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, *et al.* Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. *Lancet* 2012;379:39-46.
146. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, *et al.* A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. *J Natl Cancer Inst* 2002;94:1458-68.
147. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, *et al.* Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. *J Natl Cancer Inst* 2004;96:879-82.
148. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, *et al.* Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. *Lancet* 2011;377:813-22.
149. Smith MR, Coleman RE, Klotz L, Pittman KB, Milecki P, Ng S, *et al.* denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. *Ann Oncol* 2015;26:368-74.